Module

Targeting the Tumor Microenvironment: Ongoing Research, Clinical Updates, and Promising Applications

Source: Translating Science Into Clinical Practice: Recent Lessons in EGFR Inhibition, Multitargeted TKIs, and the Tumor Microenvironment

Targeting the Tumor Microenvironment: Ongoing Research, Clinical Updates, and Promising Applications


Faculty:

Allan Lipton, MD
  • Allan Lipton, MD

Program Director: Ezra E. W. Cohen, MD, FRCPC

CME CREDIT INFORMATION

Release Date: 09/12/08

Expiration Date: 09/11/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the incidence of bone metastases and their associated complications in several different cancers
  • Articulate the role of the RANKL/RANK cytokine system in the bone microenvironment and the formation of osteolytic metastases
  • Summarize recent data relating to the efficacy of targeting RANKL in cancer patients with metastases to the bone

Topics covered include:

  • Introduction
  • Inhibiting Osteolysis With Bisphosphonates
  • The RANK/RANKL/Osteoprotegerin System and the Bone Microenvironment
  • RANKL Inhibition in Animal Models of Bone Metastasis
  • Inhibition of RANKL in Humans
  • Baseline Bone Resorption Levels as Predictors of Treatment Efficacy
  • RANKL Inhibition and Acute-Phase Reactions
  • Future Directions
  • Conclusion
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.